Browsing Category
Pharma Industry News
4749 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
PRX012 Alzheimer’s trial: Can Prothena rebound from birtamimab setback?
After a major clinical failure, Prothena shifts focus to Alzheimer’s drug PRX012. Will this next trial restore investor confidence?
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight
Glenmark Pharmaceuticals’ ISB 2001 gets FDA Fast Track for multiple myeloma. Explore how this could redefine its biotech future and rival global oncology innovators.
Glenmark Pharmaceuticals posts 12.8% revenue rise in FY25, beats market estimates
Glenmark Pharma posts â‚ą13,894 Cr profit in FY25. Explore its global growth, R&D breakthroughs, and why ISB 2001 may define its biotech future.
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Regencell Bioscience (RGC) stock surges 26%: What’s behind the move and what investors should know
Regencell Bioscience stock spiked 26% on May 23 with no clear news. Here’s what’s behind the move and what investors should watch next.
Pfizer’s $6.05bn bet on oncology innovation: Inside the 3SBio SSGJ-707 licensing deal
Find out how Pfizer’s $6.05B deal with 3SBio could reshape the global cancer immunotherapy market with PD-1/VEGF bispecific SSGJ-707.
Univar and Shandong Head join forces to revolutionize drug delivery in Europe—Here’s what it means for pharma innovation
Univar and Shandong Head Group expand their cellulose ethers partnership into Europe—learn how this deal could redefine pharma excipient sourcing across the region.
Celltrion’s YUFLYMA gains full FDA interchangeability: What it means for U.S. biosimilar market
Discover how Celltrion’s YUFLYMA earned full FDA interchangeability, boosting biosimilar adoption and reshaping the U.S. immunology drug market.
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.
Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy
Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.